A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines

Time: 2:10 pm
day: Track A - Day 2 PM


  • Through use of an in silico screening procedure, optimal sites for conjugating a hydrophobic payload were identified
  • Compared to randomly conjugated ADCs, the site-specific ADCs were less hydrophobic and had better efficacy and exposure in an in vivo xenograft model
  • The site-specific ADCs can be manufactured using a newly discovered selective reducing agent that is able to reduce the engineered cysteines while leaving the interchain disulfides in the oxidized state